Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Cencora (NYSE:COR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

AI-generated analysis

πŸ“‰ Cencora reported Q1 CY2026 revenue of $78.36 billion, which missed Wall Street estimates of $81.51 billion by 3.9%.

πŸ“ˆ Year-on-year sales growth came in at 3.8%, reflecting a slowdown compared to the company's longer-term historical trends.

πŸ’° Non-GAAP adjusted earnings per share (EPS) were $4.75, aligning perfectly with analyst consensus estimates of $4.73.

πŸ“‰ Adjusted EBITDA fell short of expectations at $1.39 billion versus an estimated $1.44 billion, representing a 3.4% miss.

🀝 Cencora slightly raised its full-year adjusted EPS guidance to $17.78 at the midpoint following the earnings report.

πŸ“Š Operating margin remained stable at 1.5%, matching both analyst expectations and results from the same quarter last year.

πŸ’Έ Free cash flow margin declined significantly to 1.5%, down from 4.3% in the prior-year quarter, indicating tighter liquidity management.

🏒 The company generated $78.36 billion in revenue despite operating a suboptimal cost structure and modest profitability of approximately 1.3% annually.

πŸ“‰ Share count was reduced by 5.8% over five years due to stock buybacks, which contributed to EPS growth rather than operational efficiency improvements.

πŸ€– Cencora has undergone a significant rebrand from AmerisourceBergen in 2023 and focuses on connecting manufacturers with healthcare providers through logistics and data services.

🌍 The US Healthcare segment is the primary driver of revenue but has historically grown slower than the company's overall sales figures.

πŸ”­ Analysts project Cencora revenue to grow by 9% over the next 12 months, suggesting a healthy outlook despite recent quarter underperformance.

⚠️ Full-year EPS expectations stand at $16.67 for analysts, representing an anticipated 11% year-over-year growth rate.

πŸ“‰ The stock traded flat at $305 immediately after the earnings release due to mixed results with revenue miss offset by profit in-line performance.

Bullish Signals
  • Cencora's non-GAAP profit of $4.75 per share was in line with analysts' consensus estimates, demonstrating solid earnings performance despite lower revenue.
  • Management slightly raised its full-year Adjusted EPS guidance to $17.78 at the midpoint, signaling confidence in future profitability.
  • Cencora has demonstrated a strong track record of long-term growth, achieving a 10.9% annualized revenue growth over the last five years.
  • Analysts expect revenue to grow 9% over the next 12 months, which is particularly healthy for a company of its scale and suggests continued market success.
  • Over the last two years, Cencora's US Healthcare segment has averaged 7.1% year-on-year growth, indicating resilient demand in a key area.
  • Cencora's adjusted EPS grew at a compounded annual rate of 14.6% over the last five years, outpacing its revenue growth.
  • In Q1, Cencora reported adjusted EPS of $4.75 compared to $4.42 in the same quarter last year, reflecting consistent earnings expansion.
  • The company has repurchased its stock, shrinking its share count by 5.8%, which positively impacts per-share value for shareholders.
Risk Factors
  • Cencora reported Q1 CY2026 sales of $78.36 billion, missing Wall Street revenue expectations of $81.51 billion by nearly 4%.
  • The company's non-GAAP profit margin is severely depressed at just 1.5%, a level described as 'lousy' for a healthcare distributor and consistent over five years despite significant revenue growth.
  • Free cash flow margins contracted sharply from 4.3% in the prior year quarter to 1.5% in Q1, indicating deteriorating operational efficiency or increased costs.
  • Despite revenue compounding annualized growth of 10.9% over five years, operating margins have shown no improvement, raising questions about the expense base and lack of economies of scale.
  • Cencora's EPS outperformance relative to revenue is driven by financial engineering through a 5.8% reduction in share count via buybacks rather than increased operational efficiency.
  • The US Healthcare segment has underperformed the broader business, averaging only 7.1% year-on-year growth over the last two years versus higher overall sales.
  • Analysts have lowered their Q1 adjusted EBITDA estimate to $1.44 billion from Cencora's reported $1.39 billion, reflecting a 3.4% miss that persists despite guidance updates.
  • Management's raised full-year EPS guidance to $17.78 was achieved only by narrowly topping analyst expectations for full-year EPS of $16.67, suggesting limited upside buffer.
Full Analysis
Cencora (NYSE:COR) reported first-quarter sales of $78.36 billion, a 3.8% year-over-year increase that fell short of Wall Street's consensus estimate of $81.51 billion. Despite the revenue miss, the company posted non-GAAP earnings per share of $4.75, which aligned with analyst expectations of $4.73. Adjusted EBITDA came in at $1.39 billion, slightly below estimates of $1.44 billion, and the adjusted operating margin remained flat at 1.5% compared to the same period last year. Free cash flow margins declined significantly to 1.5% from 4.3% a year ago. Management revised its full-year guidance upward slightly, raising the adjusted EPS midpoint target to $17.78 after initially projecting $16.90 to $17.25. Analysts project revenue growth of 9% over the next 12 months, which would match Cencora's two-year annualized rate but fall below its long-term five-year trend of 10.9%. The company, formerly known as AmerisourceBergen, has grown its EPS at a compounded annual rate of 14.6% over the last five years, though analysts attribute this largely to share repurchases that reduced the share count by 5.8% rather than operational efficiency improvements. The stock traded flat around $305 following the earnings release. The report highlights concerns regarding Cencora's suboptimal cost structure and stagnant operating margins despite revenue growth, which limits leverage on fixed costs. While US Healthcare revenue has averaged 7.1% growth over the last two years, it has lagged the company's overall sales performance in recent quarters. The article concludes by suggesting that investors should consider valuation and broader business quality factors before deciding if the current price presents an opportunity following this mixed quarter.